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Open PHACTS is a public–private partnership between academia,
publishers, small and medium sized enterprises and pharmaceutical
companies. The goal of the project is to deliver and sustain an ‘open
pharmacological space’ using and enhancing state-of-the-art semantic
web standards and technologies. It is focused on practical and robust
applications to solve specific questions in drug discovery research. OPS is
intended to facilitate improvements in drug discovery in academia and
industry and to support open innovation and in-house non-public drug
discovery research. This paper lays out the challenges and how the Open
PHACTS project is hoping to address these challenges technically and
socially.
Introduction
Open PHACTS (Open Pharmacological Concept Triple Store) is a project funded under a European
grant from the Innovative Medicines Initiative (IMI; http://www.imi.europa.eu) [1,2] and was
born as a public–private partnership (PPP) between academia, publishers, small and medium-
sized enterprises (SMEs) and pharmaceutical companies. The ultimate goal of the project is to
deliver and sustain an ‘open pharmacological space’ (OPS). Open PHACTS will use and enhance
state-of-the-art semantic web standards [3] and technologies. It is focused on practical and robust
applications to solve specific questions in drug discovery research. The project will deliver a core
infrastructure of high-quality, semantically interoperable data accessed by user-friendly software
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Winterfaces that will enhance and accelerate the research process for
its users. When fully operational, OPS will facilitate improvements
in drug discovery in academia and industry. The OPS platform will
support open innovation and in-house non-public drug discovery
research and will collaborate on semantic interoperability with
other IMI projects regarding modeling languages, standards and
data, including supporting European infrastructure projects
including ELIXIR (http://www.elixir-europe.org/). This paper lays
out the challenges and how the Open PHACTS project is hoping to
address these challenges technically and socially.
The challenge
Research and discovery in the life sciences is amazingly complex.
Our attempts to understand the complexity of life, and the pro-
cesses associated with disease and its treatment, are reflected in the
complexity of the modern scientific process at many levels. Present
technologies now enable us to generate enormous quantities of
data. The typical scientific process produces vast amounts of
information that is dispersed and hidden in various data sources
(e.g. literature and curated databases). Data-driven life science
research, including drug discovery, will increasingly rely on a
community of collaborating partners to extract knowledge from
these sources to solve complex questions.
The development and application of innovative methods and
tools for data generation are paralleled by the needs for innovation
in data storage, curation, integration, analysis and ‘data publica-
tion’. Developments in these aspects of ‘data stewardship’ occur in
the public and private sectors and, in general, are still relatively
unguided, but offer the opportunity for important contributions
to drug discovery research (Fig. 1). The result is a diverse landscape
of data sources, with an inherent distribution of data quality,
formats, standards, copyright and licensing [4,5]. This makes dataData
commo
Individuals
Public sector
Private sector
Data type: “Crowdsourced” information,
Annotation and curation
Sharing incentives: Recognition, Publications,
Scientific profile
Requirements: Privacy standards, “opt-out”
option
Data type: Government data, Open data,
Publication supplementary data
Data type: Organizational research data
Sharing incentives: Improved services, Better
data quality, Better return on investment
Sharing incentives: Improved performance
and services, Better research, Improved
public profile
Requirements: Data licensing, “opt-out” option
Requirements: Business models, Ownership of
proprietary data
FIGURE 1
The general value of life science data across all sectors and the overall contributisharing, integration, re-use and further exploitation cumbersome,
thus hindering knowledge discovery. Therefore, many companies
have already expended considerable energy, and continue to
invest in mining clinical data, literature, patents and open- and
free-access databases. This represents an enormous duplication of
effort. Working collectively on precompetitive data integration
will reduce costs. Open PHACTS offers a mechanism for project
participants and associated collaborators to engage collectively
with state-of-the-art cutting edge semantic technology to demon-
strate the value of resource description framework (RDF) [6] and
Semantic Web technologies [3,7,8], applied directly to state-of-
the-art challenges.
The majority of current scientific advances are the result of
collective and international collaborative efforts. One of the most
important requirements to enable such efforts is that the data and
information generated are preserved in a stable, unambiguous,
trustworthy and computer readable state; Semantic Web technol-
ogies provide open standards that simplify this process, and can
significantly contribute to data and information interoperability.
From a methodological perspective the scientific process can be
seen as a workflow. Historically the analysis of only individual
observations was the principal starting point of hypothesis for-
mation. Presently computerization leads to the availability of
thousands and millions of observations. We still consider data
as individual objects but at the same time consider patterns linking
large amounts of data into common rules. This requires novel data
analysis methods to link the results of automation and high-
throughput screening approaches to the individual observations.
Advances in technologies have led to the generation of so much
data that humans cannot capture and synthesize the explicit [9],
let alone the implicit, information – this is the so-called ‘data
deluge’ [10]. Most scientific investigations in life science nowns
• Enhanced data sharing
• Integration of disparate data
• Improved predictive models
• Improved collaboration
• More drugs in pipeline
• Higher return on investment
• Better research
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bolomics, screening, biomedical imaging, analysis of data in exist-
ing databases, data in the narrative literature and medical records.
Despite this explosion in available data and information, the
volume of data does not fundamentally change the classical
biological cycle of observational research driving hypothesis for-
mation and experimental design. The primary challenge in mod-
ern biology regards the complexity of the aggregated data which
reveals ever increasing layers of complexity in the biology itself.
The construction of standardized, re-usable, stable, up-to-date and
easy to use workflow elements has emerged as the primary manner
by which to work with these complex data. A large interoperable
open data space is needed to feed these workflows.
Industry drivers
Addressing the challenges of 21st century therapeutics requires a
deep understanding of the complexities associated with the biol-
ogy of human disease. Increasingly, the industry accepts that this
knowledge can never be held within one company alone. These
challenges are leading to a change in the way pharmaceutical
companies will need to do business.
In synchrony with cost pressures, the result is a new wave of
business models in which the pharmaceutical industry is becom-
ing more open [11], leading to increased collaboration with aca-
demia and other non-profit groups and to precompetitive
collaboration between pharmaceutical companies. Furthermore,
there is now an increasing movement within the public sector to
apply resources to the discovery of new drugs. The synergy
between these developments has led to major partnership activ-
ities such as the IMI.
A comprehensive and open repository of pharmacological enti-
ties and related chemical, biological and clinical data is crucial to
drug discovery. Yet, researchers face myriad resources, databases
[12,13], websites, tools and algorithms, each covering a small
section of the space and using many different standards. The lack
of universally accepted standards significantly inhibits the ability
to integrate private, free and commercial pharmacology data to
gain a more or less comprehensive picture of the known pharma-
cological landscape. The result is that experimentalists in industry,
who are not computational experts, find it difficult to interact
meaningfully with all relevant data. To this end, many companies
spend considerable time and energy creating their own integration
frameworks to combine such data. Ultimately, these systems
mostly achieve the same results, highlighting the considerable
duplication of effort in what is arguably a precompetitive activity.
As a result there is a great need to develop a resource that addresses
this problem.
The role of the Semantic Web
Various projects have been initiated in the past decade to make
data relevant to pharmaceutical research available using a
Semantic Web context. These include Bio2RDF [14], Chem2-
Bio2RDF [15], LinkedLifeData (http://linkedlifedata.com/), Open-
Tox [16], the World Wide Web Consortium Semantic Web Health
Care and Life Sciences Interest Group (http://www.w3.org/blog/
hcls/) and others [17,18]. This resulted in many tools, including
ToxPredict (http://www.toxpredict.org/), ChESS [19] and WENDI
[20].1190 www.drugdiscoverytoday.comHowever, these have not been developed from a pharmaceutical
industry perspective. In the Open PHACTS consortium explora-
tion of user needs resulted in the following priorities:
i. Providing a sustainable pharmacological information plat-
form that would enable industry and public organizations to
share data, analyses and understanding. This should be driven
by community-endorsed open data, technical and social
standards. Such a platform could serve as a catalyst for
increased engagement and data sharing.
ii. Providing accessible, high-quality powerful tools to enable
scientists to interact and explore a unified, fully interoperable
pharmacological data space.
iii. Provide a layer of quality assessment over the data, to aid non-
experts in judging which data to incorporate in their analyses.
The Open PHACTS consortium is committed to addressing
these issues and to creating an OPS.
A driving contribution by the industrial partners in Open
PHACTS is a list of prioritized research questions often addressed
in small-molecule drug discovery and outlined below. The second
contribution is data. Companies are now depositing significant
datasets as open or free data [21] and are being encouraged to
expand their efforts to the benefit of the community [22]. One of
the barriers to increased sharing of industry data is the lack of
industrial adoption of infrastructures as well as strong incentives
to do so [23]. Various frameworks have been developed in recent
years, for general purpose and for specific data types, including
Data Dryad [24], FigShare (http://www.figshare.com), IsaTab [4]
and OpenTox [16]. These will all be evaluated and connected to
OPS where appropriate. In addition, Open PHACTS collaborates
with other IMI projects, such as eTOX (http://www.etoxprojec-
t.eu/), EHR4CR (http://www.ehr4cr.eu/) and DDMoRE (http://
www.ddmore.eu/).
The intrinsic value of data
Data contributions need to be made in a consistent manner,
ensuring reusability of the data and via a mechanism that will
be sustained for the long term. What is equally important is that
the data in the system need to be maintained, refreshed and kept
up to date. Besides the technological aspects discussed earlier there
is also an important social and legal aspect to consider: data
copyright and licensing (discussed in detail later). This is a very
important element of OPS for the industry: the structured
approach to ensure a sustainable infrastructure such that the
current seed investments can be built upon ultimately to create
an environment that becomes integral to pharmaceutical science.
Thus, lowering the barriers for data sharing in industry and
academia settings is one of the top priorities of the community-
building aspects of Open PHACTS.
The major questions
The OPS should enable research on a wide range of questions that
arise in applied pharmaceutical research, broadly covering aspects
of chemistry and biology. A multitude of potential uses of the OPS
to answer these questions can be envisaged, covering target iden-
tification and validation, the interaction profiles of compounds
and targets, exploring potential toxic interactions, applications
such as the repositioning of existing drugs to new therapeutic areas
and many others.
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BOX 1
The simplest type of research questions are related
directly to compound and/or biological target.
This subset of questions includes examples such as:
 For a given compound, summarize all ‘similar compounds’ and their
activities.
 A lead molecule is characterized by a substructure S. Retrieve all
bioactivity data in serine protease assays for molecules that contain
substructure S.
 For a specific target, which active compounds have been reported in
the literature? What is also known about upstream and downstream
targets?
 Find homologous targets to my target of interest and identify active
compounds against these homologous targets.
 For a given compound, which targets have been patented in the
context of Alzheimer’s disease?
Other questions are driven more by genetics, pathways or disease.
Examples here include:
 How does the gene variant affect patient survival for this disease?
 Who is working on the most relevant genes concerning Alzheimer’s
disease?
 For a given disease or indication provide all targets in the pathway
and all active compounds hitting them.
 What are the adverse effects of all drugs used in a given disease?
 For a particular disease what is the human expression and
distribution in healthy and diseased states?
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underlying OPS (i.e. the OPS platform) is being developed in an
agile and stepwise, user-driven fashion, focusing on the most
stringent issues for the industrial partners. Thus, the aforemen-
tioned research questions are central to driving its development
and the associated user tools. In this context a research question is
a specific query (or a series of queries) typical of the needs of
researchers involved in pharmaceutical research, in industry and
in academia.
Representatives from the European Federation of Pharmaceu-
tical Industries and Associations (EFPIA) pharmaceutical compa-
nies participating in the project generated an initial list of research
questions as part of the preparation leading to the formal OPS call
from IMI. The list was subsequently extended and refined within
the wider Open PHACTS project consortium, including the aca-
demic researchers in the pharmacological domain. True to its
precompetitive nature, the project has opted to not focus on a
single application domain or disease area but rather address the
broad interoperability and actual integration of fundamental,
quantitative, drug discovery data. The research questions serve
several purposes within the project, including:
i. encouraging adoption of agile software development techni-
ques;
ii. forming a basis for prioritizing potential data sources for
inclusion;
iii. providing quantitative success measures;
iv. guiding the development of end-user tools and visualizations;
and
v. creating a common focus for the project and a user
community.
By adopting these principles of user-driven agile development,
Open PHACTS addresses the challenges outlined in the introduc-
tion. By placing them in the context of the industry-provided use
cases, it also ensures practicality.
Scientific quality of the underlying architecture is ensured,
because the Open PHACTS project team covers a wide diversity
of expertise including fields such as systems biology, computer
science, chemo- and bioinformatics, semantics, publishing,
pharmaceutical research, assay development and screening; the
research questions have provided an excellent vehicle to converge
on a common language and to align the diverse communities
represented.
The list of potential questions (see Box 1 for examples) is
essentially infinite and the list of selected questions will grow as
the project evolves and the user community expands. It is also
difficult to define at the early stage of the project how many of
these questions OPS will be able to address efficiently during the
limited project period. Although the intention is to create a
generic architecture that can handle a wide range of different
business questions, the limited time frame will mean that only
a proportion are implemented, prioritized by factors such as
business value and availability of high-quality data sources. As a
first milestone, the consortium agreed to focus on use cases
dealing with compound–target–pathway concepts. Of course,
many cases can be answered now by industry researchers or by
academic researchers with their internal systems and via bio- and
chemo-informaticians. However, as stated above, a shared, fully
interoperable and routinely updated scientist-friendly platformfor performing these analyses in a non-manual way does not
currently exist.
As the project progresses the questions for each domain are sure
to expand in depth and complexity. A key challenge in the project
is to provide adequate guidance for inclusion and/or exclusion of
different available data sources and data types as well as resolving
queries using different vocabularies and mappings, for example
the relevant National Center for Biomedical Ontology (NCBO) set
of vocabularies and ontologies (http://bioportal.bioontology.org/
ontologies), including MeSH [25] (http://www.nlm.nih.gov/pubs/
factsheets/mesh.html) and SNOMED [26,27] or ICD11 (Interna-
tional Statistical Classification of Diseases and Related Health
Problems) for diseases. The latter is an important factor for the
combination of queries across domains to address challenging
data-mining tasks in high-content biology, target discovery and
validation.
The complexities of the challenge
The complexity of data access and licensing
Aligning the ingestion of public data and information sources with
internal proprietary data, or data obtained via acquisition, is a
challenge for the pharmaceutical industry. The academic medic-
inal chemistry research community simultaneously suffers from
lack of access to large datasets, especially those including unam-
biguously described chemical structures annotated with curated
bioactivity data. In contrast to data from general biology, where
whole organism genomes, protein sequences and protein struc-
tures are mostly available to everyone (although standardization
and curation issues still apply), chemoinformatics information haswww.drugdiscoverytoday.com 1191
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without any license can seem usable at first glance but in fact they
pose a particular problem as integration into the OPS can lead to
legal issues later. A further aspect is license incompatibilities when
data are mixed, as is anticipated in the OPS platform.
International law is not uniform regarding the copyrighting of
data and this can lead to many practical problems. This implies
that copyright and licensing terms cannot be assumed if they are
not explicitly provided by the data providers. Such provenance
information is unfortunately often missing. For example, it is
common that organizations hosting data do not specify the copy-
right details associated with data. On a more formal legal side, the
‘public domain’ concept is ill-defined under international law and
this has resulted in the formalization of the idea in copyright
waivers, where the data source formally waives any rights it may or
may not have. This approach is, for example, taken by the Creative
Commons Zero license (http://creativecommons.org/choose/
zero/). Otherwise, license incompatibilities are omnipresent in
open source software, and possibly apply to data too. An explicit
copyright and license statement is therefore crucial to enable the
sharing and repurposing of data, which in itself is required for
anyone to maintain, correct, mix and redistribute a dataset. There-
fore, solving legal and practical issues around data access, sharing
and licensing will be a focus of Open PHACTS.
The multiplicity and quality of legacy data sources
Well in excess of 100 individual resources (http://www.oxford-
journals.org/nar/database/c/) in the general field of molecular
biology are relevant for medicinal chemistry research (based on
informal polling within the Open PHACTS project). However,
there is still the urgent need for cleaning, improving and specifi-
cally for functionally connecting these data to the public domain
bioinformatics data, especially with respect to target validation,
safety, efficacy and bioavailability.
The challenges of computational processing
Ideally, to support drug discovery, ‘all’ information in biology and
chemistry contained in the classical narrative literature, datasets
such as co-expression data, GWAS data (https://www.gwascentral.
org/), curated databases and other research objects should also be
made available in a manner that facilitates computational proces-
sing. However, it is an unfortunate reality that only a frighteningly
small part of the available information is made accessible in such a
manner. Providing a limited corpus of pharmacological data that
are attuned for computational reasoning has been done before, but
Open PHACTS considers the challenge in finding the limits in
what is possible with state-of-the-art technologies.
The complexity of the name space
It is well established that the name space of biomedicine is messy
and ambiguous. Many synonyms circulate on the web for crucial
concept categories (semantic types) such as proteins, genes, drugs
and diseases, but also for institutes, authors and, for instance, units
of measurement. This historically developed disastrous situation is
tackled by various international consortia as they try collectively
to optimize the retrospective recovery of entities (concepts)
and their relationships from narrative text, databases, among
others [28]. It is an unfortunate reality that even in the ‘curated’1192 www.drugdiscoverytoday.comspace several synonymous identifiers are being used for the same
concept. Chemistry is, in many ways, even more challenged by
ambiguity and degeneracy in its identifier systems. A single com-
pound can be represented using systematic names generated
according to several conventions [29] including IUPAC, CAS
and Beilstein standards. A compound can have tens if not hun-
dreds of trivial and trade names and multiple numeric identifiers
that only have value when they can be used as look-ups against
databases. The most common numeric identifier in structure space
is the proprietary chemical abstracts service (CAS) registry number
that can be used as a lookup in a pay-wall protected database or
ideally for querying open databases. Unfortunately the uncon-
trolled proliferation of CAS numbers across public databases has
resulted in a disastrous and confused mixing of data to a state of
chaos and these numbers should not be trusted to be correct in the
public domain – only CAS retains the trusted, and expensive to
access, provenance relationship. Chemical compounds can also be
represented by numerous electronic data formats that encode their
connectivities and atomic makeup and some of these, specifically
SMILES [30] and InChIs [31], are treated as identifiers in the online
databases. However, these are defined explicitly by the atom–atom
connectivities, standardization of the chemical, the chosen cano-
nicalization algorithm and the various algorithmic settings used to
generate these identifiers. Some progress has been made with the
adoption of a standard InChIKey as a structure identifier and it is
increasingly being used to facilitate integration and connectivity
between databases. Nevertheless, the challenges of using such
confused and ambiguous labels and tokens populated by so much
variation has resulted in an enormous challenge in unraveling
databases established by mapping together these various
identifiers [32,33]. For the computer reasoning and Semantic
Web interoperability the identity mapping to unique resolvable
resource identifiers is an additional challenge of the Open PHACTS
project.
The need for community annotation
The complex and massive quantities of data available in the public
domain is of such value, but also of such magnitude and complex-
ity, that curation with any level of comprehensiveness cannot be
achieved without solid and continued involvement of the data
generating and the data consuming community – human experts
in their field [34]. Capturing data and scientific claims at the source
(from the authors and investigators) in an interoperable format
would be ideal. However, this is far from being common practice
and is susceptible to changes in understanding and perception. In
addition to the authors and creators of datasets, other contributors
and consumers of scientific information can be mobilized as
curators, ranging from students to medical practitioners to
patients. Such a ‘crowdsourced’ approach is, of course, a valuable
approach to the creation of knowledge as demonstrated by the
success of Wikipedia (http://www.wikipedia.org). In the life sciences
domain it has been carried over to, for instance, WikiGenes [35],
Gene Wiki [36], WikiPathways [37] and the ConceptWiki (http://
www.conceptwiki.org/index.php/Main%20Page), and has been
applied to the analysis of NIH chemical probes [38].
The same approach was adopted for the curation of chemical
space in the ChemSpider database [39]. Unfortunately, for greater
success in this area, more-efficient tools and greater participation
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supported by comparing data from different databases, making
detection of inconsistencies easier and by creating proper incen-
tives. As stated in one of the early Open PHACTS related publica-
tions [40]: ‘Data citation and the derivation of semantic constructs
directly from datasets have now both found their place in scientific
communication. The social challenge facing us is to maintain the
value of traditional narrative publications and their relationship to
the datasets they report upon while at the same time developing
appropriate metrics for citation of data and data constructs’.
Therefore, solutions to the central challenge of making ‘all’ bio-
logical and chemical data available in computable format to
everyone need to encompass the pure technical interoperability
aspects as well as the data and information quality issues and the
social aspects enabling modification and sharing, which again are
inseparable today from the intimate involvement of the expert
community worldwide and, thus, form proper incentives for
community curation.
Further complexity is introduced in that human language
derives much of its meaning from context. Names of entities
are not consistently used to describe the same concept. The drug
name sometimes refers to the administered medication, whereas
in other occasions is refers to the active, chemical ingredient.
The same is true for mixed references to genes in different
organisms and genes and their protein products being referred
to by the same and frequently ambiguous terms. Any community
annotation system must support addressing this aspect to support
the curation process further. These five above mentioned cate-
gories reveal the complexity of the daunting challenge facing
Open PHACTS.
The Open PHACTS solution
The Open PHACTS platform is, at its core, a data integration
platform. However, because of the complexity of the social and
technical challenges involved, the consortium decided to take a
different approach to classical data warehousing. Instead of impos-
ing a top-down view of data in data warehouses, a more bottom-up
view will be taken where information from multiple providers is
exposed by adaptive integration of the information. This bottom-
up approach will be facilitated by the adoption of open web-based
data standards. We characterize this approach as ‘semantic data
interoperability’. In essence data from all relevant sources will be
‘published’ in a semantically interoperable web enabled format,
extended by community-adopted ontologies, so that an increasing
number of tools and services, including those provided by Open
PHACTS, can take advantage of the published data layer, with full
provenance allowing access to the underlying rough datasets.
Importantly, this semantic approach to data integration has
been pioneered by other research efforts in the biomedical
domain, as outlined earlier. These research efforts have shown
that semantic data integration is feasible for life sciences in prin-
ciple. However, the addition of rich provenance and context to
individual assertions in the Semantic Web has appeared to be
crucial. Open PHACTS takes the Semantic Web approach a step
further by focusing on creating a robust, up-to-date platform,
where each and every association or assertion can be traced back
to its origin and can be placed in context, by computers and by the
human mind, and is thus designed for direct use by scientists.The data, tools, workflows and infrastructure used to develop
OPS will be open data and open source (http://github.com/open-
phacts/). All partners are contributing background intellectual
property (IP) on data, tools and software to the OPS program in
the expectation that all foreground IP generated by the OPS
program is contributed with an open license. This is a fundamental
principle that will enable the core OPS system to function as a
global drug discovery knowledge hub.
There is ample room for the development of proprietary exem-
plar services taking data feeds from the OPS infrastructure. Aca-
demic partners and SMEs in Open PHACTS will also develop
innovative exemplar services that further enhance the public drug
discovery toolset. Prospective partners that have either services
[not requiring changes beyond the Application Programming
Interface (API)] or data (published according to Open PHACTS
guidelines but not hosted in OPS) can request to become Open
PHACTS affiliated projects or partners via a straightforward pro-
cedure (essentially taking one week). Partners wishing to influence
gradually the core architecture and/or become core data providers
can follow the procedures for deeper levels of partnership while
being associated with the project already.
This scheme is essential for the sustainability approach of OPS.
Clearly, the widespread adoption of the OPS platform and the
associated standards defines the success of the project, and the
implementation of third-party services on top of the OPS infra-
structure will be a key success measure. This includes commercial
offerings and we envisage several innovative business models to
emerge. For example, a publishing house could offer high-quality
assertions as a value-added service within the OPS framework,
high-quality reasoning, patent analysis, expert finders, visualiza-
tion and query-builders interacting with OPS could be developed
by start-ups or SMEs and the OPS framework could be used to
enrich publisher content semantically.
An initial view of the OPS platform architecture is presented in
Fig. 2 but it is clear, given the agile nature of the project, that the
approach will be updated and modified over time, based on our
experiences.
Data scope
To offer maximum benefit OPS will be set up with the full realiza-
tion of the need to cover multi-omics and many other data sources.
The Open PHACTS consortium develops a software platform with
multiple installations designed to host a mixture of in-house data
from many major data ‘owners’, existing public, free and open
data, and data from further data sources that wish to expose their
content in a safe and trusted way to the OPS. Data creators and
owners will be actively approached and invited to join as asso-
ciated partners. Open PHACTS has an important role to navigate
and set policy together with the data providers, enabling users and
hosting providers to know their rights and potential legal liability.
A series of dedicated workshops is planned during the lifetime
of the project to address these crucial issues and the first of these
has already been held, in 2011 in The Netherlands (http://www.
openphacts.org/ops_workshops.htm).
The enormous and rapidly growing list of potential data sources
to be ‘semantically published’ in the OPS will not be addressed
simultaneously. As stated earlier, the prioritized research questions
will drive a stepwise inclusion needed to answer an increasingwww.drugdiscoverytoday.com 1193
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FIGURE 2
The OPS platform architecture highlighting the data feeds, the integration to a chemistry compound registration system, the semantic workflow underpinning the
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choices made in Open PHACTS will enable a scalable increase of
data sources to be covered without unacceptable performance loss.
Data acquisition
The Open PHACTS strategy centers on data publishing – in that as
many as possible of the major databases it wishes to connect
should publish their data as rich RDF, a standard for web-data
interoperability. This enables the OPS ‘data harvester’ system to
detect the presence of data (and subsequent) updates and down-
load or refer to these data, analogous to the way a search engine
crawler works. There are already several referring standards such as
VoID (http://semanticweb.org/wiki/VoiD) and nanopublications
[40], which OPS is considering. Although Open PHACTS needs to
appreciate that not every provider will be able to produce perfect
RDF, Open PHACTS has developed a set of guidelines for nanopu-
blication (see below) and will assist key data sources to publish
(subsets of) their data in compliant formats. Already, Open
PHACTS is supporting the development of standards for prove-
nance at the World Wide Web Consortium (http://www.w3.org/
2011/prov/). To encourage the publication of data, we are support-
ing approaches that enable fine-grained credit and attribution. In
particular, the project has significantly developed the original
notion of nanopublications as developed by the Concept Web
Alliance, of which several founder members are key partners in
Open PHACTS. A nanopublication is the smallest unit of publish-
able information: an assertion about anything that can be
uniquely identified, attributed to its author and de-referenced.1194 www.drugdiscoverytoday.comIn the Open PHACTS project, nanopublications will increasingly
be used to expose existing experimental data as well as assertions
retrieved from legacy data and information sources such as
scientific articles, for instance MedLine and other databases in a
standardized representation, addressing the interoperability chal-
lenge. The project has released its first set of guidelines for produ-
cing nanopublications that correspond with open standards.
Identity
The complexity of the name space is approached through a system
by which the individual concepts constituting the biological
concept space (genes, proteins, drugs/chemicals, diseases, among
others) as well as the social concept space (authors, articles,
datasets, among others) are first treated completely at the indivi-
dual concept level. Rather than trying to enforce all players
globally to refer to these individual concepts in a standard way,
the OPS will develop and use on-the-fly identity mapping to
combine different terms and internationalized resource identifiers
(IRIs) dynamically for the same physical entity. The advantage of
this approach is that different rules can be applied at query time to
fit the current query best (for instance deciding whether to treat
genes and proteins, genes and gene probes or different tautomers
or stereoisomers of the same compound as ‘the same physical
entity’ for the purposes of a query). This system will be based upon
an identity resolver and mapper and use cross-referencing data
from a range of providers, combined with profiles that capture
those query rules. Although this means Open PHACTS does not
need to mandate the use of any one specific vocabulary for a
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still provide recommendations as to how best to represent data
within the system. Specifically, Open PHACTS will recommend the
use of open public vocabularies and identifier schemes, advocating
use of resources such as the NCBO’s BioPortal (http://bioportal.
bioontology.org/ontologies) and EBI’s Ontology Lookup Service
(http://www.ebi.ac.uk/ontology-lookup/), approved vocabularies
and public identifier mapping services such as BridgeDB [41]
(http://www.bridgedb.org/) and identifiers.org (http://identifiers.
org/). Wherever possible we aim to re-use existing ontologies and
IRIs, and contribute additions and/or corrections back to the
original source. Where reliable crossmappings of ontological terms
and identifiers do not exist the ConceptWiki (http://www.
conceptwiki.org) is available to allow the community as well as
authoritative organizations to invoke crowdsourcing of mapping
between existing, and the extension of, controlled vocabularies.
Linked data cache
The OPS linked data cache interacts with the harvesting compo-
nent to gather, update and integrate data. It provides a semanti-
cally integrated view of the data by exploiting the identity
resolution and identity mapping component to construct appro-
priate responses based on the contextual aspects of each query (i.e.
what sort of user is asking for a query, what is needed to be
displayed). It also contributes to performance by caching the
semantic representations of frequently used datasets. An impor-
tant aspect of the cache is the ability to integrate datasets and
services; for example, the integration of chemical similarity search
or more-advanced reasoning components. To achieve this, Open
PHACTS will implement the cache using a semantic workflow
engine, the Large Knowledge Collider (LarKC) [42], that is speci-
fically designed for manipulating RDF data at a large scale. By
adopting this approach, the OPS should be able to integrate new
services, such as large scale reasoning, flexibly into the platform.
Additionally, LarKC provides an abstraction over a variety of
storage options for RDF data, thus providing for options to scale
as the data grows. Other reasoning environments such as associa-
tive reasoning [43–45] have already revealed novel concept con-
nections in a complementary manner to LarKC and, for instance,
WolframAlpha1 (http://www.wolframalpha.com/) will increas-
ingly be able to use the rich semantic resource the OPS will provide
to increase output.
Domain-specific services (handling chemistry)
The complexities of handling chemical compound data will be
managed by using the proven ChemSpider platform [39]. The
resource is a free-access database populated with over 26 million
unique chemical compounds linked out to over 400 data sources.
The platform includes structure searching, substructure searching
and an array of flexible search capabilities via the web-based user
interface. ChemSpider also provides access to the underlying data
and many of the underlying search routines via web services and is
the method by which the structure level data will be accessed
programmatically by the OPS system. Each chemical entity in the
Open PHACTS system is provided with a unique registration
number, a ChemSpider ID, and these IDs are populated into the
cache to facilitate linking of the data, and are complemented with
the associated SMILES and InChI Keys. Using a combination ofstructure identifiers and web services the OPS architecture can
integrate structure-based queries and the data mappings within
the cache to relate chemistry to biology.
One of the largest challenges with handling chemistry is the
appropriate representation of chemical compounds in a standar-
dized format, especially one that is acceptable to the pharmaceu-
tical industry. In this regard structure standardization routines will
be implemented according to those recommended by the FDA in
their substance registry system (SRS) documentation (http://www.
fda.gov/forindustry/datastandards/substanceregistrationsystem-
uniqueingredientidentifierunii/default.htm). The standardization
recommended by the FDA will be adjusted to match the agreed
upon needs of the Open PHACTS project defined according to a
chemistry committee of EFPIA members and chemoinformatics
representatives from the project.
Application programming interface
A key part of the OPS platform is a rich API. This interface provides
REST-style based interfaces for common queries. These queries are
defined in agile cycles working with application and user interface
developers. By driving API development from the user perspective,
Open PHACTS will also drive down the complexity of data inte-
gration by focusing on those core semantic types and properties
that are necessary for the end-users in the project.
The API is managed by LarKC enabling the flexible integration
of identifier mapping. Currently, this is implemented by generat-
ing SPARQL queries that are run over the triple store managed by
LarKC. A key principle in designing the API is to provide an
optimized robust experience for user interface and application
developers. A key difficulty in many linked data solutions today
has been the threat to performance caused by difficult or challen-
ging queries and it is not yet clear in many current prototypic
applications how to deal with complexities in the representation
of facts in RDF. By adopting a well-defined API, we can optimize
the SPARQL queries enabling us to ensure that such performance
difficulties do not occur. Finally, the API provides rich information
and access to the provenance of the results it returns. This includes
the data sources from which those results are provided including
the ability to track licensing information.
User interface
Different use cases have varying needs in terms of their interaction
with the platform. The architecture of the OPS will be flexible by
design and support a variety of end-user applications with the user
interfaces optimized to address specific tasks. Indeed, it is impor-
tant for the project to demonstrate that such a wide range of user
interfaces, focusing on different user communities, is a viable
output of the system. The OPS platform architecture provides a
balanced approach toward enabling community maintained data
sources while providing interoperability and performance. A key
novelty of the architecture is its emphasis on adaptable data
integration driven by end-user needs and customized by multiple
user interfaces and analysis workflows stemming directly from
research questions. The concept of data publication by local
data providers and a harvesting into a cache for reasoning and
querying will enable a growing number of data sources to connect
to the OPS with minimal disturbance of local procedures or
architecture.www.drugdiscoverytoday.com 1195
REVIEWS Drug Discovery Today  Volume 17, Numbers 21/22 November 2012
R
eview
s
K
E
Y
N
O
T
E
R
E
V
IE
WUsing the platform
Standards are of no value without a working implementation. To
make those standards useful, the selection of data sources for the
first generation of OPS services is a crucial issue for the success of
the Open PHACTS project. Within the project there is an active
user community representing experimental academic science as
well as industrial drug discovery. These scientists are collaborating
to build independent applications, so-called ‘exemplars’, on top of
the core semantic services. As exemplar applications mature, we
would hope that each of these be the subject of its own publica-
tion. The general approach to select and drive integration will be
guided by the defined set of frequently occurring scientific ques-
tions and drug discovery scenarios. Exemplar services are being
developed simultaneously with the design of the OPS core archi-
tecture to enable early demonstration of actual support for
ongoing drug discovery programs of the project partners. The
experience and the encountered challenges will be used to steer
the final stages of development of the wider OPS semantic infra-
structure. This is an area where the EFPIA consortium expects to
contribute significantly with expertise, curation resources and
limited data depositions.
Data quality and annotation
Open PHACTS is going to bring together several data sources from
the public domain as well as integrate and mesh data made
available by EFPIA members and commercial sources. It is promi-
nently acknowledged by the Open PHACTS project partners that
data sources (free and commercial) can be rather poorly curated
[32,46], except in those cases where significant funding is provided
to the hosting organization to police data quality and ensure that
data are kept and validated with ongoing and updated assertions.
For instance, in the chemistry space we plan to provide some
specific assessments of the quality of small-molecule representa-
tions in different databases and also annotate metrics around
chemical representation quality. At present a chemistry validation
and standardization system is in development to check for valid
chemistry representations (e.g. provide warnings when checking
for hypervalency, charge imbalance, absent stereochemistry,
among others) as well as standardization of the structure repre-
sentations across various databases to a derivative of the SRS
standard agreed upon by Open PHACTS members. These
approaches will then be applied to the data sources ingested into
Open PHACTS, data quality will be identified, detected errors will
be annotated and feedback will be provided to the data suppliers.
Several data sources have already been identified as those bring-
ing value to the Open PHACTS project. Experienced members of
the team have judged that some of these require additional levels
of curation and validation. These include data from well-known
databases such as PubChem [47], DrugBank [48,49] and ChemSpi-
der. Immediate challenges arise with the validation of the chemi-
cal entities themselves because a high proportion of the structural
representations for the chemicals/drugs/ligands in question do not
accurately represent the intended entities. Compounding this
issue is the fact that many of the associated chemical names,
synonyms and identifiers used for the purpose of text mining,
integration and cross-referencing between resources are incorrectly
associated. Add to this incorrect mapping to biological targets
and the risk of retrieving incorrect data increases significantly.1196 www.drugdiscoverytoday.comIn the biological domain as well, it is well established that even
curated databases do not nearly cover all data available in the
literature and in dispersed datasets. It is therefore probable that
current systems frequently return incomplete (when highly
curated) or misleading (when broadly recovered) results.
Quality control, rating and validation of data sources before
and after publishing into Open PHACTS will be essential and the
development of rigorous processes to define initial quality check-
ing, ongoing community validation and reporting back to the
original source providers will be necessary. Agreed upon criteria for
acceptance and rejection of data, or integrating using quality flags
for inclusion or exclusion in searches will be established across the
team. The development of high-quality validated data dictionaries
will be essential to many of the projected returns for the system
and will depend on a sincere commitment, from all parties, to
police data quality throughout the project. Importantly, the OPS
system will provide provenance of all the data it makes available
enabling users to check themselves whether the results are from
what they consider to be quality data sources.
Although data are essential to the platform under development
the annotation of these data is equally important. Annotation will
result from the ongoing process of layering on additional asser-
tions, relationships and mappings as more information flows from
the sources outlined above. However, human annotation will be
crucial to developing further the ‘assertion base’ and the contribu-
tions from participants in Open PHACTS. Crowdsourcing capabil-
ities are already delivered via three of the components of the
project: ChemSpider, ConceptWiki and WikiPathways, and it is
probable that an increasing number of easy interfaces designed to
facilitate annotation and curation will be made available. Via the
provision of selected interfaces for the purpose of adding annota-
tions to the data the growth of the underlying data will be made
more valuable via human intervention for additional knowledge
gathering.
Community crowdsourcing across industry and non-profit
organizations is a model that will be consistently explored
in Open PHACTS to provide the necessary curation resources.
Growing collaborations should enable the mitigation of the
major perceived bottlenecks for community annotation, includ-
ing the lack of a globally trusted party, the need to work with
sometimes cumbersome structured data entry interfaces and, most
importantly, the lack of professional recognition of curation and
annotation work. Open PHACTS will actively engage in building a
community that will increasingly annotate individual assertions
and the combination of these as a routine part of their daily
knowledge discovery process. In that process, Open PHACTS will
optimally involve the pioneering wiki-type crowdsourcing
approaches as well as the professional, dedicated curation com-
munities, including the International Society for Biocuration
(http://biocurator.org/).
The international perspective
Although the IMI funding model inherently limits Open PHACTS
initially to a mostly European initiative, the issues and solutions to
data interoperability are global. Most of the industrial partners in
this project have significant research activities in North America
and Asia. Many of the important data sources (NCBI, NCBO,
PubChem, DrugBank and ChEMBL, UniProt, GO) and knowledge
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within and outside Europe. Building on the principles of openness
and active re-use of established resources the Open PHACTS
project has developed an approach of ‘associate partners’ to enable
additional institutions and research groups to participate.
Close synergy with the development of ELIXIR and other devel-
oping pan-European infrastructures for life science informatics is
essential to ensure that the OPS will become a cornerstone of the
global public data infrastructure. Active collaboration will be
sought with funding agencies and other groups outside Europe
to make sure that the OPS will develop into a global platform. The
scientific activities around the globe, notably including rapidly
emerging economies in Asia and Latin America, will be engaged as
soon as feasible. Especially in community annotation the scientific
communities in these continents (including Africa) will be crucial
to the long-term success of the OPS. Therefore multilingualism
and language independence (both enabled by the Open PHACTS
conceptual approach) will be part and parcel of the policy of Open
PHACTS.
Sustainability
The development of the OPS as a major open data infrastructure
has to have a plan for sustainability, service provision and main-
tenance in the public domain once IMI project funding ceases. For
pharmaceutical industry partners to continue to invest in the
development of the OPS there must be a clear route to future
sustainability ensuring resource, as well as for investment expecta-
tions. The pharmaceutical companies will not invest in the OPS
without a sustainability and future plan to deliver on the value
proposition. Development of the OPS infrastructure necessitates a
robust service layer including change control, 24:7 support, back-
ups, disaster planning and service, which is an order of magnitude
more complicated and costly then academic best effort type appli-
cation hosting.
Open PHACTS therefore is not just another research project
with a defined ending. It is supposed to develop and deliver a
crucial, intensively used service. It is thus imperative that the OPS
as a public–private partnership (PPP) service, once established, will
be stable, high performance, user-friendly and sustainable. In
addition to the EFPIA partners in the OPS using the system for
their core research and business, it is desired and encouraged that
other organizations will also use the OPS platform. Actually it will
be a significant measure of success when other PPPs and businesses
build useful services and applications using the end result of the
Open PHACTS project.
It is obvious that making the OPS sustainable beyond the
duration of the Open PHACTS and essentially all other interde-
pendent IMI projects is crucial for all parties to enable long-term
use of the system. To ensure that the benefits are maximized for
the community, it is crucial to engage a wide community of
researchers, information providers and service companies in Eur-
ope and worldwide at an early stage of the project. More specifi-
cally, establishing dedicated human resources and sufficient
funding will have to be a mutual responsibility of the OPS partners
and the associate partner and user community to be established.
With regard to effective sustainability, Open PHACTS adopts
the principles of open data, open standards, open source, open
infrastructure and open community and free use.Conclusions
Open PHACTS clearly has the potential to initiate a paradigm shift
in the pharmacological space and far beyond. Interest has already
been shown by members of the translational research commu-
nities, the medical informatics communities, the ‘omics commu-
nities and even research fields outside the life sciences within the
first year of the project. As a result Open PHACTS has recently
established a ‘waiting room’ and a ‘gatekeeper’ function to manage
the participation of interested parties. By raising such interest and
expectations across the life science community, Open PHACTS,
and consequently IMI, has assumed a daunting responsibility. It
would be unacceptable if the OPS appeared to be technically
feasible and yet failed to deliver on expectations in terms of
accelerating drug discovery and scientific progress far beyond
the narrow ‘small-molecule space’. It would also be unacceptable
if the research performed here appeared to be yet another project
that gracefully disappeared when its funding expires. It is therefore
of importance that IMI, preferably in close coordination with
European Strategy Forum on Research Infrastructures (ESFRI)
and comparable initiatives in the USA (i.e. Sage Bionetworks,
NCBO, among others), as well as with other continents, develops
a comprehensive and widely adopted data, information and
knowledge management strategy.
The OPS system, together with the exemplars that will be
delivered during the timescale of the originally funded project,
is expected to deliver research insights. These will include devel-
oping deeper understandings of the application of Semantic Web
technologies to the life sciences, the integration and mapping of
disparate data types and sources, the influence of data quality,
crowdsourcing and curation on decision making as well as the
processes and approaches necessary to manage a diverse team to
deliver a groundbreaking technology platform. The question as to
whether the OPS platform might ultimately replace existing in-
house systems will become evident as the system is delivered to the
community as an open source software system with its associated
open data. Organizations can choose to adopt only certain com-
ponents of the overall solution or certain data slices appropriate to
address their needs. It is probable that integration between exist-
ing in-house systems and the OPS platform, using the available
programming interfaces, will provide the appropriate solution for
certain organizations in some cases. However, in many companies,
a major reason for being involved in this project is to replace
in-house systems with something that they do not have to solely
maintain, freeing up internal resources for higher-priority activ-
ities. Ultimately the success of the project will be measured by
whether or not new knowledge and wisdom can be extracted. It
would of course be beneficial if the work also resulted in new drugs
being contributed to the pipeline.
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